Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 1;317(1):107-16.
doi: 10.1016/j.yexcr.2010.10.005. Epub 2010 Oct 14.

Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis

Maria Eugenia Guicciardi  1 , Justin L Mott, Steven F Bronk, Satoshi Kurita, Christian D Fingas, Gregory J Gores
Affiliations

Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis

Maria Eugenia Guicciardi et al. Exp Cell Res. .

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a potential chemotherapeutic agent with high selectivity for malignant cells. Many tumors, however, are resistant to TRAIL cytotoxicity. Although cellular inhibitors of apoptosis 1 and 2 (cIAP-1 and -2) are often over-expressed in cancers, their role in mediating TRAIL resistance remains unclear. Here, we demonstrate that TRAIL-induced apoptosis of liver cancer cells is associated with degradation of cIAP-1 and X-linked IAP (XIAP), whereas cIAP-2 remains unchanged. Lower concentrations of TRAIL causing minimal or no apoptosis do not alter cIAP-1 or XIAP protein levels. Silencing of cIAP-1 expression, but not XIAP or cIAP-2, as well as co-treatment with a second mitochondrial activator of caspases (SMAC) mimetic (which results in rapid depletion of cIAP-1), sensitizes the cells to TRAIL. TRAIL-induced loss of cIAP-1 and XIAP requires caspase activity. In particular, caspase 8 knockdown stabilizes both cIAP-1 and XIAP, while caspase 9 knockdown prevents XIAP, but not cIAP-1 degradation. Cell-free experiments confirmed cIAP-1 is a substrate for caspase 8, with likely multiple cleavage sites. These results suggest that TRAIL-mediated apoptosis proceeds through caspase 8-dependent degradation of cIAP-1. Targeted depletion of cIAP-1 by SMAC mimetics in conjunction with TRAIL may be beneficial for the treatment of human hepatobiliary malignancies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Degradation of cIAP-1 and XIAP is associated with TRAIL-mediated apoptosis
(A) Hepatocellular carcinoma cells HuH-7 were treated with increasing concentrations of TRAIL (0–20 ng/ml). At the indicated time points, cell lysates were obtained and analyzed by immunoblotting for cIAP-1, cIAP-2, and XIAP. Actin was used as protein loading control. After 6 hours of treatment, apoptosis was assessed (B) by fluorescence microscopy after DAPI staining and (C) by measuring caspase 3/7 activation (DEVDase activity; relative fluorescence units - RFLU) with a fluorogenic assay, as described in Experimental Procedures. (D) Cholangiocarcinoma cells Mz-ChA-1 were treated with TRAIL (20 ng/ml). At the indicated time points, cell lysates were obtained and analyzed by immunoblotting for cIAP-1, cIAP-2, and XIAP. Actin was used as protein loading control. (E,F) Mz-ChA-1 were treated with increasing concentrations of TRAIL (0–20 ng/ml) and apoptosis was assessed by (E) fluorescence microscopy and (F) caspase 3/7 activation. Values of RFLU are expressed as fold increase over control value (untreated).
Figure 2
Figure 2. Knock-down of cIAP-1, but not XIAP or cIAP-2, sensitizes to TRAIL-mediated apoptosis
(A) Clones of HuH-7 cells stably transfected with shRNA against cIAP-1, cIAP-2 or XIAP were assessed by immunoblot analysis to verify efficiency of protein knock-down. Actin was included as a loading control. (B) Selected cIAP-1, cIAP-2 or XIAP shRNA clones were treated with TRAIL (5 ng/ml) for 6 hr. Apoptosis was assessed (B) morphologically and (C) by measuring caspase 3/7 activation. Data are expressed as mean ± SEM compared to TRAIL-treated HuH-7 cells. The asterisk (*) indicates statistical significance of p < 0.05.
Figure 3
Figure 3. SMAC mimetic induces loss of cIAP-1 and enhances sensitivity to TRAIL-mediated apoptosis
(A) HuH-7, Mz-ChA-1, and Hep3B cells were treated with the SMAC mimetic JP1584 (500 nM). At the indicated time points, cell lysates were obtained and expression of cIAP-1 and XIAP was analyzed by immunoblotting. Actin was used as loading control. (B,C) Cells were treated with medium alone (vehicle - Veh), or human recombinant TRAIL (HuH-7: 5 ng/ml; Mz-ChA-1: 2.5 ng/ml; Hep3B: 20 ng/ml), or JP1584 (500 nM), or a combination (TR+JP) for 6 hr. Apoptosis was quantitated (B) by morphological criteria and (C) by measuring caspase 3/7 activation. The asterisk (*) indicates statistical significance of p < 0.05.
Figure 4
Figure 4. TRAIL-mediated degradation of cIAP-1 and XIAP requires caspase activity
(A) HuH-7 cells were treated with TRAIL (20 ng/ml). At the indicated time points, cIAP-1, cIAP-2 and XIAP mRNA were quantified by real time PCR. Fold increase was determined by normalization to 18S. (B) HuH-7 cells were treated with TRAIL (20 ng/ml) in the presence or absence of the cathepsin B inhibitor CRA 025850 (10 μM; 1 hr pre-incubation), or the proteasome inhibitor MG132 (10 μM; 1 hr pre-incubation), followed by immunoblot analysis for cIAP-1 and XIAP. (C) HuH-7 cells were treated with TRAIL (20 ng/ml) in the presence or absence of the vacuolar type H+-ATPase inhibitor bafilomycin A1 (0.1 μM). Expression of cIAP1 and XIAP was assessed by immunoblot analysis. (D) HuH-7 cells were transiently transfected with a plasmid encoding HA-tagged cIAP-1 with the H588→A mutation in the RING domain, and treated with either TRAIL (20 ng/ml; left panel) or JP1582 (500 nM; right panel); cell lysates obtained at the indicated time points were analyzed by immunoblot for expression of HA-cIAP-1 using an antibody against the HA tag. Actin was used as loading control. (E) HuH-7 cells were treated with TRAIL (20 ng/ml) in the presence or absence of the pan-caspase inhibitor Q-VD-OPH (5 μM; 30 min pre-incubation). Expression of cIAP1 and XIAP was assessed by immunoblot analysis at the indicated time points. Actin was used as loading control. (F) Immunoblots for cIAP-1 from four independent experiments as described in (E) were quantified by densitometry. cIAP-1/Actin ratios were calculated and normalized to time zero, which was arbitrarily set at 100%. Data are expressed as mean ± SEM.
Figure 5
Figure 5. TRAIL-mediated degradation of cIAP-1 is caspase-8 dependent
(A) Parental HuH-7 cells or clones of HuH-7 cells stably transfected with shRNA against caspase 9 or caspase 8 were treated with TRAIL (20 ng/ml). At the indicated time points, cell lysates were obtained and analyzed by immunoblotting for cIAP-1 and XIAP; effectiveness of knockdown was verified by caspase 8 and caspase 9 immunoblot. (B) Immunoblots for cIAP-1 from independent experiments (n=3 for wild-type and 22-1; n=4 for 22-5; n=2 for 74-4 and 74-5) as described in (A) were quantified by densitometry. cIAP-1/Actin ratios were calculated at 6 hr and normalized to time zero, which was arbitrarily set at 100%. Data are expressed as mean ± SEM. (C) HuH-7 cells were treated with TRAIL (20 ng/ml) and co-immunoprecipitation of RIP1 and caspase 8 was performed at the indicated time points as described in Experimental Procedures. (D) HuH-7 cells were treated with TRAIL (20 ng/ml); total cell lysates were obtained at the indicated time points and analyzed by immunoblotting for caspase 8, RIP1, cIAP-1 and TRAF2. Actin was used as loading control. (E) Caspase 8 shRNA HuH-7 cells (clone 22-5) were treated with TRAIL (20 ng/ml); total cell lysates were obtained at the indicated time points and analyzed by immunoblotting for RIP1. Actin was used as loading control.
Figure 6
Figure 6. cIAP-1 is cleaved by caspase-8 in cell-free system and in vivo
(A) Recombinant human cIAP-1 was incubated with human recombinant active caspase 8 (1 U) or human recombinant active caspase 3 (0.5 unit), in the presence or absence of Q-VD-OPH (100 μM) for 30 minutes at 37°C and analyzed by immunoblot. Newly generated fragments are indicated by the arrows (left panel). As controls, recombinant human Bid or PARP were incubated with human recombinant active caspase 8 (0.25-1 U) or human recombinant active caspase 3 (0.5 unit), respectively, for 30 minutes at 37°C and analyzed by immunoblot (right panel). (B) HuH-7 cells were incubated with TRAIL (20 ng/ml) and MG132 (10 μM; 1 hr pre-incubation), in the presence or absence of Q-VD-OPH (5 μM) or z-IETD-fmk (10 μM). Cell lysates were analyzed by immunoblot for cIAP-1 and actin (loading control). The asterisk (*) indicates a fragment of approximately 32 kDa generated both in vivo and in the cell-free system.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66–75. - PubMed
    1. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23:1625–1637. - PMC - PubMed
    1. Salvesen GS, Dixit VM. Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A. 1999;96:10964–10967. - PMC - PubMed
    1. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 2009;4:34–41. - PubMed
    1. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008;283:24295–24299. - PMC - PubMed

Publication types

MeSH terms